长江健康(002435) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥660,212,418.11, a decrease of 24.42% compared to ¥873,535,602.23 in the same period last year[5] - The net loss attributable to shareholders was ¥10,067,346.72, representing a decline of 116.74% from a profit of ¥60,141,015.34 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0081, down 116.63% from ¥0.0487 in the previous year[5] - The net profit for Q1 2024 was -16,182,681.96 CNY, compared to a net profit of 59,052,807.21 CNY in the same period last year, indicating a significant decline[23] - Operating profit for Q1 2024 was -8,900,429.92 CNY, while the previous year reported an operating profit of 70,853,793.83 CNY, reflecting a substantial decrease[23] - The total comprehensive income for Q1 2024 was -16,174,039.43 CNY, compared to 58,565,124.24 CNY in Q1 2023, showing a drastic decline[23] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥40,621,079.98, a significant drop of 966.40% compared to a positive cash flow of ¥4,688,490.14 in the same period last year[5] - Cash flow from operating activities showed a net outflow of -40,621,079.98 CNY, compared to a net inflow of 4,688,490.14 CNY in Q1 2023[24] - Total cash and cash equivalents at the end of Q1 2024 amounted to 308,664,152.05 CNY, down from 2,401,904,913.35 CNY at the end of Q1 2023[25] - Cash and cash equivalents decreased significantly from ¥2,188,101,935.39 to ¥799,426,653.17, a decline of 63.4%[19] - The company reported cash inflows from investment activities of 2,737,538,473.49 CNY, a significant increase from 631,733,945.51 CNY in the previous year[24] - The net cash flow from financing activities was -105,756,335.19 CNY, compared to a net inflow of 444,881,419.92 CNY in Q1 2023, indicating a shift in financing strategy[25] Expenses and Liabilities - Total operating costs for Q1 2024 were ¥672,489,890.21, down 15.1% from ¥792,274,243.76 in the previous period[21] - Research and development expenses increased by 247.97% to ¥34,994,618.37, reflecting a significant rise in investment in R&D[10] - The company experienced a 59.45% reduction in selling expenses, which totaled ¥74,505,051.84, mainly due to decreased costs in the pharmaceutical sector[10] - Current liabilities totaled ¥4,114,359,330.68, down 1.8% from ¥4,188,793,635.23 in the previous period[19] - Non-current liabilities decreased to ¥699,088,467.32 from ¥759,228,969.01, a reduction of 7.9%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 45,822, with the largest shareholder holding 27.09% of the shares[11] - The company’s shareholder structure indicates significant control by the actual controllers, Yu Qianhe and Yu Xiaqiu, through Changjiang Runfa Group Co., Ltd.[12] - The top ten shareholders include Changjiang Runfa Group Co., Ltd. with 334,831,965 shares and Zhongshan Songde Zhangjiagang Free Trade Zone Pharmaceutical Industry Equity Investment Enterprise with 121,607,997 shares[12] - The company’s major shareholder, Hunan Yongxing Private Fund Management Co., holds 61,500,000 shares through a credit trading guarantee account[13] Government Support and Compliance - The company received government subsidies amounting to ¥13,362,284.73, an increase of 132.24% compared to ¥5,753,740.57 in the previous year[10] - The company has provided a violation guarantee balance of RMB 500.00 million for its controlling shareholder[15] - The company is currently under investigation by the China Securities Regulatory Commission, with no final results available as of the report date[15] - The company has engaged in non-compliant fund transfers totaling RMB 292.35 million through various intermediaries[14] Other Financial Metrics - Total assets at the end of the reporting period were ¥8,566,130,181.61, a decrease of 1.73% from ¥8,716,879,027.28 at the end of the previous year[5] - The company's total equity attributable to shareholders was ¥3,720,122,708.20, slightly down from ¥3,730,181,412.38[20] - The company has maintained a long-term investment of ¥360,000,000.00 in non-current financial assets, unchanged from the previous period[19] - The company reported a significant increase in other receivables, which rose by 107.05% to ¥3,417,280,017.47, primarily due to growth in the machinery sector[10] - The company reported a non-operating fund occupation balance of RMB 1,642.40 million as of December 31, 2023, which includes RMB 1,319.00 million from discounted commercial acceptance bills[14] - As of the report date, the non-operating fund occupation balance from the controlling shareholder and related parties increased to RMB 3,625.41 million[15] - The company’s subsidiary, Changjiang Runfa (Zhangjiagang) Steel Co., Ltd., transferred non-operating funds of RMB 1,930.00 million to the controlling shareholder in early January 2024[15] Strategic Focus - The company’s financial report indicates a focus on expanding its investment in health-related sectors[17] - The company has not reported any new product launches or significant market expansion strategies during this quarter[26]